Clinical Case Studies in Venous Thromboembolism: Addressing Clinical Issues in Special Patient Populations
|
|
- Aubrey Perry
- 6 years ago
- Views:
Transcription
1 Clinical Case Studies in Venous Thromboembolism: Addressing Clinical Issues in Special Patient Populations Presented as a Live Webinar Wednesday, May 10, :00 PM 3:00 PM ET On-demand Activity Live webinar recorded and archived to be watched at your convenience Available after May 25, This activity is sponsored and planned by the American Society of Health-System Pharmacists (ASHP). Supported by an educational grant from the Bristol-Myers Squibb and Pfizer Alliance Copyright 2017, American Society of Health-System Pharmacist, Inc. All rights reserved.
2 Clinical Case Studies in Venous Thromboembolism: Addressing Clinical Issues in Special Patient Populations Activity Overview Clinical case studies will be used to illustrate approaches for addressing clinical issues related to the use of direct oral anticoagulants (DOACs) for managing venous thromboembolism in three patient populations: patients with cancer-associated thrombosis, kidney disease, and obesity. Strategies for managing potential drug interactions with DOACs will also be discussed. Learning Objectives At the conclusion of this application-based educational activity, participants should be able to Examine the evidence for use of direct oral anticoagulants (DOACs) with venous thromboembolism (VTE) and kidney disease Review the evidence for the use of DOACs in patients with cancer-associated VTE Review data on the use of DOACs for treatment of VTE in patients with obesity Implement an appropriate strategy for managing potential drug interactions with DOACs Continuing Education Accreditation The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity provides 1.0 hour (0.1 CEU no partial credit) of continuing pharmacy education credit. Live Activity ACPE #: L01-P On-demand Activity ACPE #: H01-P The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The American Society of Health-System Pharmacists designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Participants will process CE credit online at For pharmacist participants, CPE credit will be reported directly to CPE Monitor. Per ACPE, CE credit must be claimed no later than 60 days from the date of the live activity or completion of a home-study activity. 2
3 Clinical Case Studies in Venous Thromboembolism: Addressing Clinical Issues in Special Patient Populations List of Abbreviations For a list of abbreviations used in this activity, please see page 36. Webinar Information Visit to find Webinar registration link Group viewing information and technical requirements CE webinar processing information Additional Educational Activities in this Initiative On-demand activities Web-based activities for the 3-part webinar series available in May 2017 (1 hour CE each, please note that individuals who claim CE credit for a live webinar are ineligible to claim credit for the corresponding web-based activity) 3
4 Clinical Case Studies in Venous Thromboembolism: Addressing Clinical Issues in Special Patient Populations Faculty Adam C. Cuker, M.D., M.S. Assistant Professor of Medicine and Pathology & Laboratory Medicine Perelman School of Medicine University of Pennsylvania Philadelphia, Pennsylvania Adam C. Cuker, M.D., M.S., is Assistant Professor of Medicine and of Pathology and Laboratory Medicine at the University of Pennsylvania Perelman School of Medicine in Philadelphia. He also serves as Director of the Penn Comprehensive Hemophilia and Thrombosis Program and Associate Director of the Penn- CHOP Blood Center for Patient Care and Discovery. Dr. Cuker received his Doctor of Medicine degree from Yale University in New Haven and completed an internship and residency in internal medicine at Brigham and Women s Hospital and Harvard Medical School in Boston. He continued his postgraduate training as a fellow in hematology/oncology at the Hospital of the University of Pennsylvania. Dr. Cuker also holds a Master of Science in Translational Research degree from the University of Pennsylvania. He is board certified in internal medicine and hematology and is a fellow of the American College of Physicians. Dr. Cuker conducts patient-oriented research on heparin-induced thrombocytopenia, venous thromboembolism, and anticoagulation funded by the National Institutes of Health. He is Chair of the forthcoming American Society of Hematology (ASH) guidelines on venous thromboembolism and Chair of the ASH panel on heparin-induced thrombocytopenia. 4
5 Clinical Case Studies in Venous Thromboembolism: Addressing Clinical Issues in Special Patient Populations Paul P. Dobesh, Pharm.D., BCPS-AQ Cardiology, FCCP Professor of Pharmacy Practice College of Pharmacy University of Nebraska Medical Center Omaha, Nebraska Paul P. Dobesh, Pharm.D., BCPS-AQ Cardiology, FCCP, is Professor of Pharmacy Practice at the University of Nebraska Medical Center (UNMC) College of Pharmacy in Omaha, Nebraska. Dr. Dobesh earned both his Bachelor of Science in pharmacy and Doctor of Pharmacy degrees from South Dakota State University. He completed a specialty residency in internal medicine at the University of Texas at Austin at Brackenridge Hospital. He is a board-certified pharmacotherapy specialist with added qualifications in cardiology. Dr. Dobesh currently maintains clinical practice with cardiology services at Nebraska Medical Center. He is responsible for teaching pharmacy and medical students, as well as pharmacy and medical residents. His main lecture topics include ischemic heart disease, antithrombotic therapy, and other cardiology and critical care topics. Dr. Dobesh has conducted research on antiplatelet and antithrombotic therapy, focusing on the real-world use of these therapies and healthcare economics. He has also published book chapters and several manuscripts in this area. Dr. Dobesh was awarded the Distinguished Educator of the Year Award at the UNMC College of Pharmacy in 2015, an award he received four times since In 2013, he was honored with the UNMC campuswide Outstanding Educator Award. 5
6 Disclosures Clinical Case Studies in Venous Thromboembolism: Addressing Clinical Issues in Special Patient Populations In accordance with the Accreditation Council for Continuing Medical Education s Standards for Commercial Support and the Accreditation Council for Pharmacy Education s Standards for Commercial Support, ASHP requires that all individuals involved in the development of activity content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual or his or her spouse/partner has a financial relationship (e.g. employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring in the last 12 months with a commercial interest whose products or services may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on the content. All faculty and planners for ASHP education activities are qualified and selected by ASHP and required to disclose any relevant financial relationships with commercial interests. ASHP identifies and resolves conflicts of interest prior to an individual s participation in development of content for an educational activity. Anyone who refuses to disclose relevant financial relationships must be disqualified from any involvement with a continuing pharmacy education activity. Paul P. Dobesh, Pharm.D., BCPS-AQ Cardiology, FCCP, declares that he has served as a consultant for Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb and Pfizer Alliance, Daiichi Sankyo, Janssen Pharmaceuticals, Inc., and Portola Pharmaceuticals, Inc. (Faculty) Alpesh Amin, M.D., MBA, FACC, MACP, SFHM, declares that he has served as a consultant for Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb and Pfizer Alliance, and Portola Pharmaceuticals, Inc. (Steering Committee) Toby C. Trujillo, Pharm.D., BCPS-AQ Cardiology, FAHA, FCCP, declares he has served as a consultant for Bristol-Myers Squibb and Pfizer Alliance and Janssen Pharmaceuticals, Inc. (Steering Committee) All other faculty and planners report no financial relationships relevant to this activity. 6
7 Clinical Case Studies in Venous Thromboembolism: Addressing Clinical Issues in Special Patient Populations Adam C. Cuker, M.D., M.S. University of Pennsylvania, Perelman School of Medicine Philadelphia, Pennsylvania Paul P. Dobesh, Pharm.D., BCPS AQ Cardiology, FCCP University of Nebraska Medical Center, College of Pharmacy Omaha, Nebraska Disclosures of Faculty and Planners Paul P. Dobesh, Pharm.D., BCPS AQ Cardiology, FCCP, declares that he is a consultant for Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers Squibb and Pfizer Alliance, Daiichi Sankyo, Janssen Pharmaceuticals, Inc., and Portola Pharmaceuticals, Inc. (Faculty) Toby C. Trujillo, Pharm.D., BCPS AQ Cardiology, FAHA, FCCP, declares that he has served as a consultant for the Bristol Myers Squibb and Pfizer Alliance and Janssen Pharmaceuticals, Inc. (Steering Committee) Alpesh Amin, M.D., MBA, FACC, MACP, SFHM, declares that he has served as a consultant for Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers Squibb and Pfizer Alliance, and Portola Pharmaceuticals, Inc. (Steering Committee) All other faculty and planners report no financial relationships relevant to this activity 7
8 Learning Objectives At the conclusion of this educational activity, participants should be able to Examine the evidence for use of direct oral anticoagulants (DOACs) with venous thromboembolism (VTE) and kidney disease Review the evidence for the use of DOACs in patients with cancer associated VTE Review data on the use of DOACs for treatment of VTE in patients with obesity Implement an appropriate strategy for managing potential drug interactions with DOACs DOACs in Patients with VTE and Renal Insufficiency 8
9 Case 1 A 78 year old man with chronic kidney disease is admitted for pulmonary embolism. He is stabilized on heparin and is ready to be transitioned to an oral anticoagulant. His CrCl is 22 ml/min. Which of the following is appropriate oral therapy? a. Apixaban 10 mg BID x 1 week, then 5 mg BID b. Apixaban 10 mg BID x 1 week, then 2.5 mg BID c. Dose adjusted warfarin (INR goal = 2 3) d. Edoxaban 60 mg daily e. Rivaroxaban 15 mg BID x 3 wk, then 15 mg daily Renal exclusion criteria in clinical trials DOAC Renal Clearance Pivotal Trial(s) Renal Exclusion Criterion Dabigatran 80% RE COVER RE COVER II Rivaroxaban 36% EINSTEIN DVT EINSTEIN PE CrCl < 30 ml/min CrCl < 30 ml/min Apixaban 25% AMPLIFY CrCl < 25 ml/min or SCr > 2.5 mg/dl Edoxaban 35% HOKUSAI VTE CrCl < 30 ml/min Schulman S et al. N Engl J Med. 2009; 361: Schulman S et al. Circulation. 2014; 129: EINSTEIN Investigators et al. N Engl J Med. 2010; 363: EINSTEIN PE Investigators et al. N Engl J Med. 2012; 366: Agnelli G et al. N Engl J Med. 2013; 369: HOKUSAI VTE Investigators et al. N Engl J Med. 2013; 369:
10 Overall Results Recurrent VTE Major Bleeding RR 0.90 ( ) RR 0.61 ( ) Republished with permission of American Society of Hematology from van Es N et al. Blood. 2014; 124: ; permission conveyed through Copyright Clearance Center, Inc. Results stratified by renal function Recurrent VTE RR 0.70 ( ) RR 0.97 ( ) Major Bleeding RR 0.51 ( ) RR 0.60 ( ) Republished with permission of American Society of Hematology from van Es N et al. Blood. 2014; 124: ; permission conveyed through Copyright Clearance Center, Inc. 10
11 Similar results in Phase III non valvular atrial fibrillation DOAC trials GFR Stroke/Systemic Embolism RR (95% CI) Major Bleeding RR (95% CI) ml/min 0.71 ( ) 0.88 ( ) < 50 ml/min 0.79 ( ) 0.80 ( ) Del Carpio Munoz F et al. Am J Cardiol. 2016; 117: Real world studies: More data to come Study Population (n) n XALIA GARFIELD VTE Dresden NOAC registry RE COVERY DVT/PE Patients with VTE treated with rivaroxaban Patients with VTE treated with DOACs or VKA Patients with VTE or NVAF treated with DOACs Patients with VTE treated with dabigatran or VKA ,000 (target) ,000 (target) Beyer Westendorf J et al. Thromb Haemost. 2016; 116(suppl 2):S13 S23. Ageno W et al. Thromb Haemost. 2017; 117:
12 Evidence in severe renal dysfunction (CrCl < 30 ml/min) or end stage renal disease DOAC Dabigatran Rivaroxaban Apixaban Edoxaban FDA approved DOAC labeling for VTE treatment in renal impairment Creatinine Clearance > 30 ml/min 30 ml/min 30 ml/min < 30 ml/min 30 ml/min < 30 ml/min > 50 ml/min ml/ min < 15 ml/min Dosing Recommendation 150 mg BID No dosage recommendation 15 mg BID x 3 wk, then 20 mg daily Not recommended 10 mg BID x 7 days, then 5 mg daily No dosage recommendation 60 mg daily* 30 mg daily Not recommended *30 mg daily if weight 60 kg or receiving certain P glycoprotein inhibitors. 12
13 What do I do? In patients with CrCl 30 ml/min I use DOACs as first line treatment If the CrCl is ml/min, I have a slight preference for a factor Xa inhibitor over dabigatran In patients with CrCl < 30 ml/min I avoid DOACs I use warfarin In patients with CrCl > 95 ml/min I use another DOAC in preference to edoxaban (based on experience in non valvular atrial fibrillation) Key Takeaways DOACs have non inferior efficacy and superior safety compared with warfarin in patients with VTE and CrCl 30 ml/min Therefore, DOACs should be considered first line treatment in this population DOACs have not been studied in patients with VTE and CrCl < 30 ml/min Therefore, DOACs should be avoided in this population 13
14 Case 1 A 78 year old man with chronic kidney disease is admitted for pulmonary embolism. He is stabilized on heparin and is ready to be transitioned to an oral anticoagulant. His CrCl is 22 ml/min. Which of the following is appropriate oral therapy? a. Apixaban 10 mg BID x 1 week, then 5 mg BID b. Apixaban 10 mg BID x 1 week, then 2.5 mg BID c. Dose adjusted warfarin (INR goal = 2 3) d. Edoxaban 60 mg daily e. Rivaroxaban 15 mg BID x 3 wk, then 15 mg daily DOACs in Patients with Cancer associated VTE 14
15 Case 2 HW is a 60 year old man who was diagnosed with stomach cancer about 6 months ago. Today he presents with a proximal DVT in his left leg. He has normal hepatic and renal function. He would like to avoid injectable therapy. Which of the following is the best treatment for HW s DVT? a. Warfarin for 6 months b. Apixaban 10 mg twice daily x 21 days, then 5 mg twice daily c. Edoxaban 30 mg once daily d. Rivaroxaban 15 mg twice daily x 21 days, then 20 mg daily e. Dabigatran 150 mg twice daily ACCP Antithrombotic Guideline, 10 th edition (AT 10) AT 10 Choice of anticoagulant for long term treatment of DVT and PE: In patients with DVT of the leg or PE and no cancer, as long term (first 3 months) anticoagulant therapy, we suggest dabigatran, rivaroxaban, apixaban, or edoxaban over VKA therapy (Grade 2B) Remarks: Acute therapy with parenteral anticoagulation is given before dabigatran and edoxaban In patients with DVT of the leg or PE who receive extended therapy, we suggest that there is no need to change the choice of anticoagulant after the first 3 months (Grade 2C). ACCP = American College of Chest Physicians Kearon C et al. Chest. 2016; 149:
16 ACCP AT 10 Guideline Statement AT 10 Choice of anticoagulant for long term treatment of DVT and PE: In patients with DVT of the leg or PE and cancer ( cancerassociated thrombosis ), as long term (first 3 months) anticoagulant therapy, we suggest LMWH over VKA therapy (Grade 2C), dabigatran (Grade 2C), rivaroxaban (Grade 2C), apixaban (Grade 2C), or edoxaban (Grade 2C). Remarks: Acute therapy with parenteral anticoagulation is given before dabigatran and edoxaban. See text for factors that influence choice of therapy. Kearon C et al. Chest. 2016; 149: VTE Treatment in Cancer Patients: Initial dalteparin dose 200 units/kg/day Randomized to dalteparin 150 units/kg/day or warfarin (INR 2 3) n = 676 Significant reduction in VTE at 6 months with dalteparin Mortality: dalteparin 39% vs. dalt/warfarin 41% (p = 0.53) LMWH vs. Warfarin 25% 20% 15% 10% 5% 0% Dalteparin Oral anticoagulant p=0.09 p= % 17% 8% Recurrent VTE p=0.27 6% 4% Major Bleeding 14% Any Bleeding Lee A et al. N Engl J Med. 2003; 349:
17 VTE Treatment in Cancer Patients: LMWH vs. Warfarin Enoxaparin 1.5 mg/kg/day vs. warfarin (INR 2 3) n = 146 (cancer and VTE) Duration: 3 months Primary outcome: recurrent VTE and/or major bleeding, warfarin 21.1% vs. enoxaparin 10.5% (p = 0.09) Fatal bleeding: warfarin 8% vs. enoxaparin 0% (p = 0.03) Mortality: warfarin 22.7% vs. enoxaparin 11.3% (p = 0.07) Enoxaparin p=0.04 Warfarin Reproduced with permission from Meyer G et al. Arch Intern Med. 2002; 162: Copyright 2002 American Medical Association. All rights reserved. ACCP AT 10 Guideline Statement AT 10 Choice of anticoagulant for long term treatment of DVT and PE: In patients with DVT of the leg or PE and cancer ( cancerassociated thrombosis ), as long term (first 3 months) anticoagulant therapy, we suggest LMWH over VKA therapy (Grade 2C), dabigatran (Grade 2C), rivaroxaban (Grade 2C), apixaban (Grade 2C), or edoxaban (Grade 2C). Remarks: Acute therapy with parenteral anticoagulation is given before dabigatran and edoxaban. See text for factors that influence choice of therapy. Pages In patients with VTE and cancer who are not treated with LMWH, we do not have a preference for either a NOAC or VKA. There is no preference of one NOAC over another NOAC Kearon C et al. Chest. 2016; 149:
18 DOAC VTE Trials and Dosing RECOVER I and II At least 5 days of injectable anticoagulation followed by dabigatran 150 mg twice daily EINSTEIN DVT and PE Rivaroxaban 15 mg twice daily for 21 days, then 20 mg daily AMPLIFY Apixaban 10 mg twice daily for 7 days, then 5 mg twice daily Hokusai VTE At least 5 days of injectable anticoagulation followed by edoxaban 60 mg once daily Acute VTE Treatment: Clinical Trial Comparisons DOAC vs. Warfarin (or VKA) Characteristic RE COVER I & II (dabigatran) EINSTEIN DVT & PE (rivaroxaban) AMPLIFY (apixaban) Hokusai VTE (edoxaban) Recurrent VTE 2.4 vs vs vs vs. 2.9 VTE mortality 0.1 vs vs vs vs. 0.6 Total mortality 1.8 vs vs vs vs. 3.1 Major bleeding 1.4 vs vs vs vs. 1.6 Major + CRNM bleeding 5.3 vs vs vs vs. 10 Dobesh PP et al. Drugs. 2014; 74:
19 Characteristic Acute VTE Treatment: Clinical Trial Comparisons RE COVER I RE COVER II EINSTEIN DVT EINSTEIN PE AMPLIFY Hokusai VTE Mean age (yr) Male sex (%) Weight (kg) CrCl ml/min (%) NR NR Active cancer (%) VTE history (%) DVT only (%) PE only (%) DVT + PE (%) NR = not reported Dobesh PP et al. Drugs. 2014; 74: Patients with Active Cancer: Primary Efficacy Endpoint % of Patients 8% 6% 4% 2% 0% None of these comparisons are statistically significant DOAC 7.1% 7.1% 6.4% Standard Care 4.7% 5.1% 3.5% 3.7% 3.7% RE COVER I & II EINSTEIN DVT & AMPLIFY Hokusai VTE PE n=221 n=597 n=159 n=208 Schulman S et al. Circulation. 2014; 129; Prins MH et al. Thromb J. 2013; 11:21. Agnelli G et al. Poster at European Society of Cardiology (ESC) Congress. Barcelona, Spain; 2014 Sep 2. The Hokusai VTE Investigators. N Engl J Med. 2013; 369:
20 % of Patients 30% 25% 20% 15% 10% 5% 0% Patients with Active Cancer: Safety Endpoints 15.2% 15.8% 12.6% EINSTEIN DVT & PE None of these comparisons are statistically significant 22.5% 18.3% 25.3% DOAC Standard Care 5.8% 5.0% 2.8% 2.3% AMPLIFY Hokusai VTE EINSTEIN DVT & PE AMPLIFY Major Bleeding Major + CRNM Bleeding Prins MH et al. Thromb J. 2013; 11:21. Agnelli G et al. Poster presented at ESC Congress. Barcelona, Spain; 2014 Sep 2. The Hokusai VTE Investigators. N Engl J Med. 2013; 369: VTE Treatment in Cancer Patients: Initial dalteparin dose 200 units/kg/day Randomized to dalteparin 150 units/kg/day or warfarin (INR 2 3) n = 676 Significant reduction in VTE at 6 months with dalteparin Mortality: dalteparin 39% vs. dalt/warfarin 41% (p = 0.53) LMWH vs. Warfarin 25% 20% 15% 10% 5% 0% Dalteparin Oral anticoagulant p=0.09 p= % 17% 8% Recurrent VTE p=0.27 6% 4% Major Bleeding 14% Any Bleeding Lee A et al. N Engl J Med. 2003; 349:
21 Case 2 HW is a 60 year old man who was diagnosed with stomach cancer about 6 months ago. Today he presents with a proximal DVT in his left leg. He has normal hepatic and renal function. He would like to avoid injectable therapy. Which of the following is the best treatment for HW s DVT? a. Warfarin for 6 months b. Apixaban 10 mg twice daily x 21 days, then 5 mg twice daily c. Edoxaban 30 mg once daily d. Rivaroxaban 15 mg twice daily x 21 days, then by 20 mg daily e. Dabigatran 150 mg twice daily DOACs in Patients with VTE and Obesity 21
22 Case 3 A 42 year old morbidly obese woman (124 kg, BMI 47.0 kg/m 2 ) is on indefinite anticoagulation with warfarin for a history of recurrent unprovoked VTE. She asks if she can switch to one of the new drugs. How do you advise her? a. Switch to a DOAC safer and more convenient than warfarin b. Switch to apixaban more effective than warfarin in patients of her size when weight based dose is used c. Do not switch DOACs less effective than warfarin in patients of her size d. Do not switch paucity of evidence on DOAC use in patients of her size Weight based enrollment in clinical trials DOAC Volume of distribution Pivotal Trial(s) Weight categories Enrollment (%) Dabigatran L RE COVER RE COVER II Rivaroxaban ~50 L EINSTEIN DVT EINSTEIN PE 100 kg BMI 35 kg/m 2 > 100 kg BMI > 35 kg/m 2 > 90 kg > 90 kg 502/2539 (20%) 306/2539 (12%) 438/1280 (34%) 302/1280 (24%) 245/1731 (14%) 345/2419 (14%) Apixaban ~21 L AMPLIFY 100 kg BMI > 35 kg/m 2 522/2691 (19%) 349/2691 (13%) Edoxaban 107 L HOKUSAI VTE > 100 kg 611/4118 (15%) Schulman S et al. N Engl J Med. 2009; 361: Schulman S et al. Circulation. 2014; 129: EINSTEIN Investigators et al. N Engl J Med. 2010; 363: EINSTEIN PE Investigators et al. N Engl J Med. 2012; 366: Agnelli G et al. N Engl J Med. 2013; 369: HOKUSAI VTE Investigators et al. N Engl J Med. 2013; 369: Martin K et al. J Thromb Haemost. 2016; 14:
23 Overall Results Recurrent VTE Major Bleeding RR 0.90 ( ) RR 0.61 ( ) Republished with permission of American Society of Hematology from van Es N et al. Blood. 2014; 124: ; permission conveyed through Copyright Clearance Center, Inc. Recurrent VTE Results in high body weight* subgroup Bleeding, M+CRNM *Cut off for defining high BW was 100 kg in 4 trials and 90 kg in 2 trials. Di Minno MN et al. Ann Med. 2015; 47:61 8. Permission by Copyright Clearance Center Inc., on behalf of Taylor & Francis Ltd. 23
24 PK/PD data Rivaroxaban 10 mg single dose study in healthy volunteers Parameter kg (n=12) >120 kg (n=12) AUC (ng ml 1 hr) C max (ng/ml) t 1/2 (hr) Apixaban 10 mg single dose study in healthy volunteers Parameter kg (n=16) >120 kg (n=19) AUC (ng ml 1 hr) C max (ng/ml) t 1/2 (hr) Kubitza D et al. J Clin Pharmacol. 2007; 47: Upreti VV et al. Br J Clin Pharmacol. 2013; 76: FDA approved DOAC labeling for VTE treatment in obesity DOAC Dosing for VTE in patients with obesity Dabigatran No dosage recommendation Rivaroxaban No dosage recommendation Apixaban Edoxaban No dosage recommendation No dosage recommendation 24
25 International Society on Thrombosis and Haemostasis recommendations We suggest that DOACs should not be used in patients with a BMI > 40 kg/m 2 or a weight > 120 kg. IfaDOACisusedinapatientwithaBMI>40kg/m 2 or a weight > 120 kg, we suggest checking a peak and trough drug level. If the level falls within the expected range, continuation of the DOAC seems reasonable. If the level is found to be below the expected range, we suggest changing to a VKA rather than adjusting the dose of the DOAC. Martin K et al. J Thromb Haemost. 2016; 14: Key Takeaways DOACs appear to have a non inferior efficacy and safety profile compared with VKA in patients with body weight of kg and/or BMI of kg/m 2. Therefore, DOACs may be considered as a first line treatment option in this population. Very few data are available on DOAC use in patients with body weight > 120 kg and/or BMI > 40 kg/m 2. Therefore, DOACs should be avoided in this population. If a DOAC is used, measurement of drug levels should be considered. 25
26 Case 3 A 42 year old morbidly obese woman (124 kg, BMI 47.0 kg/m 2 ) is on indefinite anticoagulation with warfarin for a history of recurrent unprovoked VTE. She asks if she can switch to one of the new drugs. How do you advise her? a. Switch to a DOAC safer and more convenient than warfarin b. Switch to apixaban more effective than warfarin in patients of her size when weight based dose is used c. Do not switch DOACs less effective than warfarin in patients of her size d. Do not switch paucity of evidence on DOAC use in patients of her size Drug Interactions with DOACs 26
27 Case 4 TS is a 50 year old man with a history of multiple DVTs. He has been receiving apixaban 5 mg twice daily for about 5 months. He falls acutely ill and is diagnosed with invasive aspergillosis and needs to be started on voriconazole. He has a CrCl of 60 ml/min and normal hepatic function. What is the best approach to managing his anticoagulation therapy? a. Continue on apixaban 5 mg twice daily b. Change to rivaroxaban 15 mg once daily c. Change to dabigatran 75 mg twice daily d. Change to apixaban 2.5 mg twice daily e. Change to warfarin 7.5 mg daily DOAC Drug Interaction Potential Dabigatran IIa inhibitor Esterase mediated hydrolysis when absorbed Absorption dependent on P glycoprotein Minimal (20%) hepatic metabolism not CYP3A4 Approximately 80% renal elimination Rivaroxaban Xa inhibitor Absorption dependent on P glycoprotein Approximately 65% metabolized by hepatic CYP3A4 and CYP2J3 Approximately 35% renal elimination Apixaban Xa inhibitor Absorption dependent on P glycoprotein Approximately 73% metabolized by hepatic CYP3A4 Approximately 27% renal elimination Edoxaban Xa inhibitor Absorption dependent on P glycoprotein Approximately 50% hepatic metabolism, but only 4% CYP3A4 Approximately 50% renal elimination Heiduchel H et al. Europace. 2015; 17:
28 P Glycoprotein (P gp): A Drug Transport Protein Substrate Intestinal lumen Intestinal wall P-gp Plasma Normal activity of the P gp efflux mechanism in the GI tract Present in liver, kidney, brain, capillaries, placenta, and GI tract Functions as an efflux pump to prevent absorption of certain drugs that are P gp substrates Adapted from DuBuske LM. Drug Safety. 2005; 28: Mechanism of P Glycoprotein Drug Interactions Substrate Intestinal lumen Intestinal wall Inhibitor P-gp Plasma Effect of inhibition on the P gp efflux mechanism Drugs that inhibit P gp will increase absorption of a substrate, increasing its serum concentrations Drugs that induce P gp will decrease absorption of a substrate, reducing its serum concentrations Adapted from DuBuske LM. Drug Safety. 2005; 28:
29 Interplay Between CYP3A4 and P gp Bailey DG et al. CMAJ. 2004; 170: Copied under license from Access Copyright. Further reproduction, distribution, or transmission is prohibited, except as otherwise permitted by law. P Glycoprotein Drug Interactions Inducers clotrimazole St. John s wort midazolam nifedipine phenobarbital phenytoin rifampin Inhibitors amiodarone cefoperazone ceftriaxone clarithromycin cyclosporine diltiazem dipyridamole erythromycin hydrocortisone itraconazole ketoconazole nicardipine nifedipine propranolol quinidine quinine tacrolimus tamoxifen verapamil 29
30 CYP3A4 Drug Interactions Inducers carbamazepine efavirenz glucocorticoids nevirapine phenobarbital phenytoin primidone rifampin rifapentine ritonavir St. John s wort Inhibitors amiodarone amprenavir aprepitant atazanavir cimetidine clarithromycin cyclosporine diltiazem erythromycin fluconazole fluoxetine fluvoxamine grapefruit juice indinavir itraconazole ketoconazole lopinavir nefazodone nelfinavir quinidine quinupristin and dalfopristin ritonavir saquinavir verapamil voriconazole DOAC Drug Interactions More drugs interact with DOACs than outlined in the DOAC product labeling EHRA guidelines provide useful information on increases in AUC of DOACs based on available data Clinical trial exclusion criteria for concomitant drugs with interaction potential are an important consideration when reviewing product labeling EHRA: European Heart Rhythm Association Heidbuchel H et al. Europace. 2015; 17: January CT et al. J Am Coll Cardiol. 2014; 64:e1 e76. 30
31 Dabigatran Drug Interactions Mechanism Interacting Medication P gp induction rifampin P gp inhibition with CrCl ml/min ketoconazole dronedarone Effect Recommendation stroke risk, avoidcombination bleeding risk, consider dose reduction to 75 mg BID P gp inhibition with CrCl ml/min amiodarone, verapamil, ketoconazole, bleeding risk, avoid combination dronedarone, diltiazem, clarithromycin Pharmacodynamic interaction aspirin, clopidogrel, NSAIDs bleeding risk, assess risks and benefits Pradaxa (dabigatran etexilate mesylate) prescribing information Nov. Rivaroxaban Drug Interactions Mechanism Interacting Medication Strong dual CYP 3A4 & P gp induction rifampin, phenytoin, carbamazepine St. John s wort Strong dual CYP 3A4 & P gp inhibition conivaptan, HIV protease inhibitors, itraconazole, ketoconazole Weak to moderate CYP 3A4 & P gp inhibition & CrCl ml/min amiodarone, verapamil, diltiazem, erythromycin, dronedarone, cimetidine Pharmacodynamic interaction aspirin, clopidogrel, NSAIDs Effect Recommendation stroke risk, avoidcombination bleeding risk, avoid combination bleeding risk, avoid combination unless benefit exceeds risk, concurrent administration was allowed in ROCKET AF Trial bleeding risk, assess risks and benefits Xarelto (rivaroxaban) prescribing information Mar. 31
32 Apixaban Drug Interactions Mechanism Interacting Medication Strong dual CYP 3A4 & P gp induction rifampin, phenytoin, carbamazepine, St. John s wort Strong dual CYP 3A4 & P gp inhibition itraconazole, ketoconazole, ritonavir, clarithromycin Effect Recommendation stroke risk, avoidcombination If on 2.5 mg BID: bleeding risk, avoid combination If on > 2.5 mg BID: bleeding risk, reduce dose by 50% Pharmacodynamic interaction aspirin, clopidogrel, NSAIDs bleeding risk, assess risks and benefits Eliquis (apixaban) prescribing information Apr. Edoxaban Drug Interactions Mechanism Interacting Medication P gp induction rifampin P gp inhibition atrial fibrillation P gp inhibition VTE verapamil, quinidine, azithromycin, clarithromycin, erythromycin, itraconazole, ketoconazole Pharmacodynamic interaction aspirin, clopidogrel, NSAIDs Effect Recommendation stroke risk, avoidcombination No dose reductions; dose reduction in those on P gp inhibitors in trial resulted in lower than expected concentrations bleeding risk, reduce dose to 30 mg daily; adjust dose upward after short term P gp inhibitor administration if no other indication for dose decrease present bleeding risk, assess risks and benefits Savaysa (edoxaban) prescribing information Apr. 32
33 DOAC Drug Interactions DOACs are substrates of P gp and CYP 450 system Dependence on CYP 3A4 for metabolism rivaroxaban > apixaban > edoxaban Despite similar mechanisms of drug interactions, considerable variability in product labeling May need to consider renal function along with concomitant drugs Labeling for managing drug interactions varies across international regulatory agencies Aspirin significantly increases bleeding risk with all DOACs, evaluate concomitant indication Case 4 TS is a 50 year old man with a history of multiple DVTs. He has been receiving apixaban 5 mg twice daily for about 5 months. He falls acutely ill and is diagnosed with invasive aspergillosis and needs to be started on voriconazole. He has a CrCl of 60 ml/min and normal hepatic function. What is the best approach to managing his anticoagulation therapy? a. Continue on apixaban 5 mg twice daily b. Change to rivaroxaban 15 mg once daily c. Change to dabigatran 75 mg twice daily d. Change to apixaban 2.5 mg twice daily e. Change to warfarin 7.5 mg daily 33
34 Which of these practice changes will you consider making? Select all that apply. a. Share info about DOACs in challenging situations with interprofessional team b. Include DOACs as option after LMWH for CAassociated thrombosis c. Review regimens to consider potential DOAC drug interactions d. Educate patients above DOAC weight cutoffs about VTE options e. If lack of evidence, educate patients to facilitate informed decision Selected Resources DOACs in Patients with VTE and Renal Insufficiency van Es N, Coppens M, Schulman S et al. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood. 2014; 124: Del Carpio Munoz F, Gharacholou SM, Munger TM et al. Meta analysis of renal function on the safety and efficacy of novel oral anticoagulants for atrial fibrillation. Am J Cardiol. 2016; 117: DOACs in Patients with Cancer associated VTE Kearon C, Akl EA, Ornelas J et al. Antithrombotic therapy for VTE disease. CHEST Guideline and Expert Panel Report. Chest. 2016; 149: Dobesh PP, Fanikos J. New oral anticoagulants for the treatment of venous thromboembolism: understanding differences and similarities. Drugs. 2014; 74:
35 DOACs in Patients with VTE and Obesity Di Minno MN, Lupoli R, Di Minno A et al. Effect of body weight on efficacy and safety of direct oral anticoagulants in the treatment of patients with acute venous thromboembolism: a meta analysis of randomized controlled trials. Ann Med. 2015; 47:61 8. Martin K, Beyer Westendorf J, Davidson BL et al. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J Thromb Haemost. 2016;14: Drug Interactions with DOACs Selected Resources Heidbuchel H, Verhamme P, Alings M et al. Updated European Heart Rhythm Association practical guide on the use of non vitamin K antagonist anticoagulants in patients with non valvular atrial fibrillation. Europace. 2015; 17:
36 Clinical Case Studies in Venous Thromboembolism: Addressing Clinical Issues in Special Patient Populations Abbreviations Used in Presentation ACCP AUC BID BMI BW CI CrCl CRNM DOAC DVT EHRA ESRD FDA GFR INR ISTH LMWH M M+CRNM NOAC NSAIDs P-gp PE PK/PD RR t 1/2 VKA VTE American College of Chest Physicians area under curve twice daily body mass index body weight confidence interval creatinine clearance clinically relevant nonmajor direct oral anticoagulant deep vein thrombosis European Heart Rhythm Association end-stage renal disease Food and Drug Administration glomerular filtration rate International Normalized Ratio International Society on Thrombosis and Haemostasis low molecular weight heparin mortality major + clinically relevant nonmajor non-vitamin K oral anticoagulant nonsteroidal antiinflammatory drugs P-glycoprotein pulmonary embolism pharmacokinetic/pharmacodynamic relative risk half-life vitamin K antagonist venous thromboembolism 36
37 Clinical Case Studies in Venous Thromboembolism: Addressing Clinical Issues in Special Patient Populations Self-assessment Questions 1. Which of the following direct oral anticoagulants is most dependent on the kidneys for clearance? a. Apixaban b. Dabigatran c. Edoxaban d. Rivaroxaban 2. Based on current evidence, which of the following statements regarding the data with DOACs in treating cancer-associated VTE is TRUE? a. DOACs have significantly better efficacy compared with warfarin. b. DOACs have demonstrated similar safety compared with LMWH. c. DOACs have demonstrated similar efficacy compared with warfarin. d. DOACs have significantly worse safety compared with warfarin. e. DOACs are preferred to LMWH as a first-line treatment option. Also see the polling questions within the activity. Answers 1. b 2. c 37
Drug Use Criteria: Direct Oral Anticoagulants
Texas Vendor Drug Program Drug Use Criteria: Oral Anticoagulants Publication History 1. Developed March 2017. 2. Revised February 2018. Notes: Information on indications for use or diagnosis is assumed
More informationPractical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease
Practical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease Cyrille K. Cornelio, Pharm.D. PGY2 Cardiology Pharmacy Resident The University of Oklahoma College of Pharmacy
More informationOral Anticoagulants Update. Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation
Oral Anticoagulants Update Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation Objectives List the direct oral anticoagulant (DOAC) drugs currently available Describe
More informationDOAC for VTE. Direct Oral Anticoagulants Clint Shedd DNP, FNP-BC Emory University
DOAC for VTE Direct Oral Anticoagulants Clint Shedd DNP, FNP-BC Emory University No disclosures Direct Oral Anticoagulants Understand VTE and the ACCP s position on it List the DOACs available in the US
More informationNew Anticoagulants Therapies
New Anticoagulants Therapies Rachel P. Rosovsky, MD, MPH October 22, 2015 Conflicts of Interest No disclosures 2 Agenda 3 Historical perspective Novel oral anticoagulants Stats Trials Approval Concerns/Limitations
More informationDirect Oral Anticoagulants
Direct Oral Anticoagulants Holly Jahn, PharmD, CACP Objectives Identify the FDA approved indications for use, appropriate dosing, and monitoring parameters for each direct oral anticoagulant. Distinguish
More informationSouthern Trust Anticoagulant Team
CLINICAL GUIDELINES ID TAG Title: Author: Speciality / Division: Directorate: Anticoagulation- Primary Care Guidance for reviewing patients on DOACs Southern Trust Anticoagulant Team Haematology Acute
More informationOral Anticoagulation Drug Class Prior Authorization Protocol
Oral Anticoagulation Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationDirect Oral Anticoagulant Use in Older Adults Brian Skinner, PharmD
Direct Oral Anticoagulant Use in Older Adults Brian Skinner, PharmD Dr. Skinner serves as an Assistant Professor of Pharmacy Practice at Manchester University, and he is one of three Internal Medicine
More informationUpdates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism
Disclosures Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism No financial conflicts of interest Member of the ABIM Focused- Practice in Hospital Medicine Self Examination Process
More informationDirect Oral Anticoagulants: Determining Proper Use and Dose
Direct Oral Anticoagulants: Determining Proper Use and Dose Toby C. Trujillo, Pharm.D., BCPS-AQ Cardiology, FAHA, FCCP Associate Professor University of Colorado Skaggs School of Pharmacy and Pharmaceutical
More informationClinical Guideline for Anticoagulation in VTE
Clinical Guideline for Anticoagulation in VTE These clinical guidelines are intended to provide evidence-based recommendations regarding the anticoagulation in patients with DVT and PE. Please note that
More informationAnticoagulation: Novel Agents
Anticoagulation: Novel Agents Scott C. Woller, MD Medical Director, Anticoagulation Management, Intermountain Healthcare Central Region, co-director Venous Thromboembolism Program, Intermountain Medical
More informationDirect Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT
Direct Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT OAC WARFARIN Gold standard DABIGATRAN RIVAROXABAN APIXABAN EDOXABAN BETRIXABAN
More informationOutpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2015
Outpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2015 General Principles: There is compelling data in the medical literature to support
More informationLet s Gi e The So ethi g To Clot About: Controversies in Anticoagulation
Let s Gi e The So ethi g To Clot About: Controversies in Anticoagulation Janna Beavers, MS, PharmD, BCPS Cardiology Clinical Pharmacy Specialist WakeMed Health & Hospitals Raleigh, NC March 13, 2018 Pharmacist
More informationUPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS
UPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS Armando Mansilha MD, PhD, FEBVS 16 th National Congress of the Italian Society of Vascular and Endovascular Surgery Bologna, 2017 Disclosure I have the following
More informationNibal R. Chamoun, Pharm.D., BCPS Clinical Assistant Professor of Pharmacy Practice at the Lebanese American University Clinical Pharmacy Coordinator
Nibal R. Chamoun, Pharm.D., BCPS Clinical Assistant Professor of Pharmacy Practice at the Lebanese American University Clinical Pharmacy Coordinator at LAUMCRH Review the mechanism of action, indications
More informationWhat s new with DOACs? Defining place in therapy for edoxaban &
What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas
More informationAnticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging
Anticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging Scott C. Woller, MD Co-Director, Thrombosis Program Intermountain Medical
More informationA Review of Direct-Acting Oral Anticoagulants (DOACs) and Their Use in Special Populations
A Review of Direct-Acting Oral Anticoagulants (DOACs) and Their Use in Special Populations Allison Bernard, PharmD PGY2 Ambulatory Care Resident University of Iowa Hospitals and Clinics October 25 th,
More informationClinical issues which drug for which patient
Anticoagulants - a matter of heart! Towards a bright future? Clinical issues which drug for which patient Sabine Eichinger Dept. of Medicine I Medical University of Vienna/Austria Conflicts of interest
More informationNew and old anticoagulants. Anticoagulation Focus on Direct Oral Anticoagulants
Anticoagulation Focus on Direct Oral Anticoagulants Tzu-Fei Wang, MD Assistant Professor Department of Internal Medicine Division of Hematology The Ohio State University Wexner Medical Center Objectives
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Oral Anticoagulants Page 1 of 7 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Oral Anticoagulant - Bevyxxa (betrixaban), Eliquis (apixaban), Pradaxa (dabigatran),
More informationMaster Class: DOAC Drug Interactions April 20, 2017
Master Class: DOAC Drug Interactions April 20, 2017 Sara R. Vazquez, PharmD, BCPS, CACP Clinical Pharmacist University of Utah Health Thrombosis Service Disclosures Financial Disclosures: none Off-label/investigational
More informationUSE OF DIRECT ORAL ANTICOAGULANTS IN OBESITY
SDSHP ANNUAL MEETING CLINICAL PEARLS APRIL 7 TH, 2017 USE OF DIRECT ORAL ANTICOAGULANTS IN OBESITY STEFFANIE DANLEY, PHARM D, BCPS, CACP DISCLOSURE I have had no financial relationship over the past 12
More informationWarfarin for Long-Term Anticoagulation. Disadvantages of Warfarin. Narrow Therapeutic Window. Warfarin vs. NOACs. Challenges Monitoring Warfarin
1 2:15 pm The Era of : Selecting the Best Approach to Treatment SPEAKER Gregory Piazza, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Gregory Piazza,
More informationDrug Class Monograph
Drug Class Monograph Class: Oral Anticoagulants Drug: Coumadin (warfarin), Eliquis (apixaban), Pradaxa (dabigatran), Savaysa (edoxaban), arelto (rivaroxaban) Formulary Medications: Eliquis (apixaban),
More informationApixaban for Atrial Fibrillation in Patients with End-Stage Renal Disease on Dialysis
Apixaban for Atrial Fibrillation in Patients with End-Stage Renal Disease on Dialysis Caitlin Reedholm, PharmD PGY1 Pharmacy Resident St. David s South Austin Medical Center November 2, 2018 Abbreviations
More informationUpdates in Management of Venous Thromboembolic Disease
Updates in Management of Venous Thromboembolic Disease November 7 th 2018 UHN Emergency Conference Susan Jenkins RN(EC) NP-Adult Thrombosis and Hemostasis Program University Health Network Disclosures
More informationWhen and How to Use the Newly Approved Oral Anticoagulants to Treat Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Ian del Conde, MD
When and How to Use the Newly Approved Oral Anticoagulants to Treat Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Ian del Conde, MD December 12, 2015 Disclosures CONSULTANT Merck; New Haven
More informationNew Antithrombotic Agents DISCLOSURE
New Antithrombotic Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau None Research Alexion (PNH) delought@ohsu.edu Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University What
More informationMEDICAL ASSISTANCE BULLETIN
ISSUE DATE July 5, 2016 SUBJECT EFFECTIVE DATE July 11, 2016 MEDICAL ASSISTANCE BULLETIN NUMBER *See below BY Prior Authorization of Anticoagulants - Pharmacy Services Leesa M. Allen, Deputy Secretary
More informationTim Brown, PharmD, BCACP, FASHP Director of Clinical Pharmacotherapy, Akron General Medical Center for Family Medicine Professor, Northeast Ohio
Tim Brown, PharmD, BCACP, FASHP Director of Clinical Pharmacotherapy, Akron General Medical Center for Family Medicine Professor, Northeast Ohio Medical University Objectives 1. 2. 3. 4. Review and discuss
More informationNEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS
NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS OBJECTIVES: To provide a comparison of the new/novel oral anticoagulants (NOACs) currently available in Canada. To address
More informationThe clinical relevance of AMPLIFY programme
Venice October 16th 2015 The clinical relevance of AMPLIFY programme Francesco Dentali Department of Clinical Medicine Insubria University Varese Disclosures Bayer Bristol-Myers Squibb/Pfizer Boehringer
More informationKelly Rudd, PharmD, FCCP, BCPS, CACP Basset Medical Center, Cooperstown, NY
Jedi Training 101: Mind-tricks & Evidence -Based Approaches to Combating Clinical Controversies in Anticoagulation Therapy Kelly Rudd, PharmD, FCCP, BCPS, CACP Basset Medical Center, Cooperstown, NY LEARNING
More informationResults from RE-COVER RE-COVER II RE-MEDY RE-SONATE EXECUTIVE SUMMARY
Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE Results from
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization
MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants
More informationComparison of novel oral anticoagulants (NOACs)
Comparison of novel oral anticoagulants (NOACs) For guidance for full information refer to individual SPCs available at www.medicines.org.uk Licensed indications for NOACs Prevention of stroke and systemic
More informationNOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS
NOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS OBJECTIVES: To provide a comparison of the newer direct oral anticoagulants (DOACs) currently available in Canada. To address frequently-asked questions
More informationThe DOACs. Update on Anticoagulation 10/20/2017. Dabigatran (Pradaxa ) Rivaroxaban (Xarelto ) Apixaban (Eliquis ) Edoxaban (Savaysa ) Objectives
Objectives Update on Anticoagulation JEFF REIST PHARMD, BCPS CLINICAL ASSOCIATE PROFESSOR UNIVERSITY OF IOWA COLLEGE OF PHARMACY At the conclusion of this program, the participant should be able to: List
More informationEdoxaban. Direct Xa inhibitor Direct thrombin inhibitor Direct Xa inhibitor Direct Xa inhibitor
This table provides a summary of the pharmacotherapeutic properties, side effects, drug interactions and other important information on the four anticoagulant medications currently in use or under review
More informationAnticoagulation Update: VTE Guidelines update, DOACs, procedural warfarin interruption, and icentra (whew!)
Anticoagulation Update: VTE Guidelines update, DOACs, procedural warfarin interruption, and icentra (whew!) Clinical Learning Day 2017 Scott C. Woller, MD Co-Director, Thrombosis Program Intermountain
More informationJoshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine
Joshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine Antithrombotics Antiplatelets Aspirin Ticlopidine Prasugrel Dipyridamole
More informationOral rivaroxaban versus standard therapy for the acute and continued treatment of symptomatic deep vein thrombosis. The EINSTEIN DVT study.
Oral rivaroxaban versus standard therapy for the acute and continued treatment of symptomatic deep vein thrombosis. The EINSTEIN DVT study Comments Harald Darius, Berlin Disclosures for Harald Darius Research
More informationNew areas of development for the direct oral anticoagulants
New areas of development for the direct oral anticoagulants Varese March 2016 Disclosures for Harry R Büller Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Scientific Advisory
More informationRenal Function Considerations for Stroke Prevention in Atrial Fibrillation
Renal Function Considerations for Stroke Prevention in Atrial Fibrillation Wednesday, March 28, 2018, 1:00PM ET Presenters: John Fanikos, RPh, MBA Curt Mahan, PharmD Paul Dobesh, PharmD, FCCP, BCPS Presenters
More informationAbstract. Background. Methods
Abstract Background Malignancy is a major risk factor for developing venous thromboembolism (VTE), and thus cancer patients are at high risk for deep vein thrombosis (DVT) and/or pulmonary embolism (PE).
More informationAnticoagulation Beyond Coumadin
Anticoagulation Beyond Coumadin Saturday, September 21, 2013 Crystal Mountain Resort and Spa Pratik Bhattacharya MD, MPH Stroke Neurologist, Michigan Stroke Network; Assistant Professor of Neurology; Wayne
More informationNew Antithrombotic Agents
New Antithrombotic Agents Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau None What I am Talking About 1. New Antithrombotic
More informationRETROSPECTIVE CLAIMS DATABASE STUDIES OF DIRECT ORAL ANTICOAGULANTS (DOACS) FOR STROKE PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION
RETROSPECTIVE CLAIMS DATABASE STUDIES OF DIRECT ORAL ANTICOAGULANTS (DOACS) FOR STROKE PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION Craig I. Coleman, PharmD Professor, University of Connecticut School
More informationUpdate on Oral Anticoagulants. Dr. Miten R. Patel Cancer Specialists of North Florida Cell
Update on Oral Anticoagulants Dr. Miten R. Patel Cancer Specialists of North Florida Cell 904-451-9820 Email miten.patel@csnf.us Overview Highlights of the 4 new approved oral anticoagulants Results from
More informationAppendix IV - Prescribing Guidance for Apixaban
Appendix IV - Prescribing Guidance for Apixaban Patient Factors Dose of Apixaban If your patient has any of the following MAJOR risk factors: Hypersensitivity to the active substance or to any of the excipients
More informationIndications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute
Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma
More informationDEEP VEIN THROMBOSIS (DVT): TREATMENT
DEEP VEIN THROMBOSIS (DVT): TREATMENT OBJECTIVE: To provide an evidence-based approach to treatment of patients presenting with deep vein thrombosis (DVT). BACKGROUND: An estimated 45,000 patients in Canada
More informationDOACs and CAT. 05 May 2017 NTW St Thomas Hospital
DOACs and CAT Alexander (Ander) Cohen Vascular Medicine / Haematology Guy s and St Thomas Hospitals, King s College, London 05 May 2017 NTW St Thomas Hospital Disclosures for Dr. Alexander (Ander) T. Cohen
More informationSpontane und Tumor-assoziierte VTE: womit wie lange antikoagulieren
Spontane und Tumor-assoziierte VTE: womit wie lange antikoagulieren Paul Kyrle Allgemeines Krankenhaus Wien Disclosures relevant for this presentation Consultancies, member of advisory boards, speaker
More informationDIRECT ORAL ANTICOAGULANTS
2017 Cardiovascular Symposium DIRECT ORAL ANTICOAGULANTS ERNESTO UMAÑA, MD, FACC ORAL ANTICOAGULANTS Vitamin K Antagonists (VKAs): Warfarin Non Vitamin K Antagonists Direct oral anticoagulants Novel Oral
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC DEBATE: DOAC vs Good Old Warfarin André Roussin MD, FRCP, CSPQ CHUM and ICM/MHI Associate professor University of Montreal A. Roussin
More informationTreatment Options and How They Work
Treatment Options and How They Work Robin Offord Director of Clinical Pharmacy UCL Hospitals NHS Foundation Trust robin.offord@uclh.nhs.uk Introducing the term anticoagulant... What they do Inhibit the
More informationObesity, renal failure, HIT: which anticoagulant to use?
Obesity, renal failure, HIT: which anticoagulant to use? Mark Crowther with thanks to Dr David Garcia and others. This Photo by Unknown Author is licensed under CC BY-SA 1 2 Drug choices The DOACs have
More informationXarelto (rivaroxaban)
Xarelto (rivaroxaban) Policy Number: 5.01.575 Last Review: 7/2018 Origination: 6/2014 Next Review: 7/2019 LoB: ACA Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Xarelto
More informationThe Direct Oral Anticoagulants: Practical Considerations. David Garcia, MD University of Washington Seattle Cancer Care Alliance September 2015
The Direct Oral Anticoagulants: Practical Considerations David Garcia, MD University of Washington Seattle Cancer Care Alliance September 2015 Disclosure Occasional consultant to : BMS, Pfizer, Daiichi
More informationWMC PHARMACY ANTICOAGULATION PROTOCOL Current Revision: July 2017 GENERAL ORDER PROCESSING AND MANAGEMENT
WMC PHARMACY ANTICOAGULATION PROTOCOL Current Revision: July 2017 GENERAL ORDER PROCESSING AND MANAGEMENT - Entering orders for anticoagulation in Cerner Providers will enter individual orders (oneoffs)
More informationDIRECT ORAL ANTICOAGULANTS: WHEN TO USE, WHICH TO CHOOSE AND MANAGEMENT OF BLEEDING
DIRECT ORAL ANTICOAGULANTS: WHEN TO USE, WHICH TO CHOOSE AND MANAGEMENT OF BLEEDING KATHERINE STIRLING CONSULTANT PHARMACIST ANTICOAGULATION AND THROMBOSIS DR LISHEL HORN CONSULTANT HAEMATOLOGIST HAEMOSTASIS
More informationDOAC the story so far... Dr GM Benson Director NI Haemophilia and Thrombosis Centre BHSCT
DOAC the story so far... Dr GM Benson Director NI Haemophilia and Thrombosis Centre BHSCT A rose by any other name.. Recommendation on the nomenclature for oral anticoagulants: communication from the SSC
More informationLa terapia del TEV nel paziente oncologico nell'era dei DOAC
XXVI CONGRESSO NAZIONALE FCSA Bologna, 5-7 Novembre 2015 Tromboembolismo venoso La terapia del TEV nel paziente oncologico nell'era dei DOAC ANNA FALANGA Immunoematologia e Medicina Trasfusionale e Centro
More informationAre the days of Warfarin numbered?
2 nd SAVTE Symposium Are the days of Warfarin numbered? YES Dr. Mohamed A. Abdelaal, MD, FRCPath, FRCPI Consultant Haematologist King Abdulaziz Medical City - Jeddah, Saudi Arabia 1 3 May 2012, Casablanca,
More informationA Review of the Role of Non-Vitamin K Oral Anticoagulants in the Acute and Long-Term Treatment of Venous Thromboembolism
Cardiol Ther (2018) 7:1 13 https://doi.org/10.1007/s40119-018-0107-0 REVIEW A Review of the Role of Non-Vitamin K Oral Anticoagulants in the Acute and Long-Term Treatment of Venous Thromboembolism Andrew
More informationDOACs in CAT. Fellow: Shweta Jain, MD Faculty Discussant: David Garcia, MD
DOACs in CAT Fellow: Shweta Jain, MD Faculty Discussant: David Garcia, MD Case 65 year old post menopausal female Left breast lesion Oct 2015 Biopsy Invasive ductal carcinoma Lumpectomy with SNB- pt1cno
More informationCancer Associated Thrombosis An update.
Cancer Associated Thrombosis An update. Simon Noble Marie Curie Professor of Supportive and Palliative Medicine Marie Curie Palliative Care Research Centre Cardiff University The coagulation pathway LIQUID
More informationEvidences for real-life use in fragile patients: Renal failure and cancer
Evidences for real-life use in fragile patients: Renal failure and cancer Cecilia Becattini Medicina Interna e Cardiovascolare Stroke Unit Università di Perugia Approval number: L.IT.MA.11.2016.1839 Evidences
More informationUpdates in venous thromboembolism. Cecilia Becattini University of Perugia
Updates in venous thromboembolism Cecilia Becattini University of Perugia News for VTE Diagnosis Treatment the acute phase the agents Pulmonary embolism: diagnosis Vein ultrasonography Meta-analysis 15
More informationDaiichi Sankyo s Once-Daily Lixiana
Daiichi Sankyo s Once-Daily Lixiana (edoxaban) Receives Positive CHMP Opinion for the Prevention of Stroke and Systemic Embolism in Non-Valvular Atrial Fibrillation and for the Treatment and Prevention
More informationClinical Policy: Dabigatran (Pradaxa) Reference Number: CP.PMN.49 Effective Date: Last Review Date: 05.18
Clinical Policy: (Pradaxa) Reference Number: CP.PMN.49 Effective Date: 05.01.12 Last Review Date: 05.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationNOAC s across indications
Sektion CAMPUS INNENSTADT Med. Klinik und Poliklinik IV NOAC s across indications Ulrich Hoffmann, M.D. Division of Vascular Medicine University Hospital Munich, Germany Disclosure Speaker name: Ulrich
More informationEdoxaban for the treatment and prevention of venous thromboembolism (DVT or PE) or stroke prevention in non-valvular AF
Edoxaban for the treatment and prevention of venous thromboembolism (DVT or PE) or stroke prevention in non-valvular AF Traffic light classification- Amber 2 specialist initiation / recommendation Information
More informationA Clinical Context Report
Stroke Prevention in Atrial Fibrillation An Expert Commentary With Kenneth W. Mahaffey, MD A Clinical Context Report Stroke Prevention in Atrial Fibrillation Expert Commentary Jointly Sponsored by: and
More informationThe Use of New Anticoagulants in the Elderly NOACs, DOACs,TOACs,TSOACs.
The Use of New Anticoagulants in the Elderly NOACs, DOACs,TOACs,TSOACs. Chris E. Holmes MD, PhD Assistant Director, Thrombosis and Hemostasis Program University of Vermont Dabigatran (Praxxada) Rivoraxaban
More informationSurvey patients for Sx, signs of AF. Establish AF Dx. Evaluate & Tx underlying heart disease/other causes. Assess adequacy of rate or rhythm control
Suggested General Approach to Managing Atrial Fibrillation Survey patients for Sx, signs of AF Establish AF Dx ECG Holter Event monitor Implanted device (pacer) Determine & Tx stroke risk (CHA 2 DS 2 VASc)
More informationPradaxa (dabigatran)
Pradaxa (dabigatran) Policy Number: 5.01.574 Last Review: 7/2018 Origination: 6/2014 Next Review: 7/2019 LoB: ACA Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Pradaxa
More informationMy Cancer Patient Has a Clot- Can I prescribe a Direct Oral Anticoagulant (DOAC)?
My Cancer Patient Has a Clot- Can I prescribe a Direct Oral Anticoagulant (DOAC)? November 24, 2018 Erica Peterson MD, FRCPC University of British Columbia Disclosures I participate in clinical research
More informationAcute Care: Understanding Direct Oral Anticoagulants (DOACs)
Acute Care: Understanding Direct Oral Anticoagulants (DOACs) National Conference for Nurse Practitioners (NCNP) October 11, 2017 John Togami, PharmD, PhC Pharmacist Clinician - Outpatient Anticoagulation
More informationNOACs in AF. Dr Colin Edwards Auckland Heart Group and Waitemata DHB. Dr Fiona Stewart Auckland Heart Group and Auckland DHB
NOACs in AF Dr Colin Edwards Auckland Heart Group and Waitemata DHB Dr Fiona Stewart Auckland Heart Group and Auckland DHB Conflict of Interest Dr Fiona Stewart received funding from Pfizer to attend the
More informationNew Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY
New Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY Fact VTE is deadly! It nibbles after it bites! The 30-day mortality rates for first-time DVT or
More informationAnticoagulation Update: DOACs, VTE Guidelines, Bridging and icentra
Anticoagulation Update: DOACs, VTE Guidelines, Bridging and icentra (whew!) Scott C. Woller, MD Co Director, Thrombosis Program Intermountain Medical Center Professor of Medicine University of Utah School
More informationGetting the Most from DOAC Therapy:
Getting the Most from DOAC Therapy: Minimizing Risk and Maximizing Adherence Brent N. Reed, Pharm.D., BCPS AQ Cardiology University of Maryland School of Pharmacy Stuart T. Haines, Pharm.D., BCPS, BCACP,
More informationESC Congress 2012, Munich
ESC Congress 2012, Munich Anticoagulation in Atrial Fibrillation 2012: Which Anticoagulant for Which Patient? Stefan H. Hohnloser J.W. Goethe University Frankfurt am Main S.H.H. has served as a consultant,
More informationAtrial Fibrillation. 2 nd Annual National Hospitalist Conference San Antonio, TX September 7, 2018
2 nd Annual National Hospitalist Conference San Antonio, TX September 7, 2018, MSc, FACP, SFHM Division of Hospital Medicine Henry Ford Hospital Detroit, USA Clinical Associate Professor of Medicine Wayne
More informationAn Overview of Non Vitamin-K Antagonist Oral Anticoagulants. Helen Williams Consultant Pharmacist for CV Disease South London
An Overview of Non Vitamin-K Antagonist Oral Anticoagulants Helen Williams Consultant Pharmacist for CV Disease South London Contents Drugs and drug classes Licensed indications and NICE recommendations
More informationADC Slides for Presentation 02/10/2017
ADC 2017 Slides for Presentation ANTI THROMBOTIC THERAPY FOR NON VALVULAR ATRIAL FIBRILLATION IN PATIENTS WITH CHRONIC KIDNEY DISEASE: CURRENT VIEWS Martin A. Alpert, MD Brent M. Parker Professor of Medicine
More information3/19/2012. What is the indication for anticoagulation? Has the patient previously been on warfarin? If so, what % of the time was the INR therapeutic?
Abigail E. Miller, PharmD, BCPS Clinical Specialist, Cardiology University of North Carolina Hospitals I have no personal financial relationships with the manufacturers of the products to disclose. Boehringer
More informationEngage AF-TIMI 48. Edoxaban in AF: What can we expect? Cardiology Update John Camm. St. George s University of London United Kingdom
Cardiology Update 2013 N S N O N H O H N S1 pocket Aryl binding N site O O N H N Cl Engage AF-TIMI 48 Edoxaban in AF: What can we expect? John Camm St. George s University of London United Kingdom Advisor
More informationUHL Guideline for Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in adults, with Direct Oral Anti-Coagulants
UHL Guideline for Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in adults, with Direct Oral Anti-Coagulants Trust Ref B11/2018 1. Introduction and Who Guideline applies to The introduction
More informationAcute VTE Care Transition Order Set (Adult)
Administration DOCUMENT PURPOSE This order set may be used for adult patients diagnosed with venous thromboembolism (VTE: deep vein thrombosis, pulmonary embolism) who are ready to be transferred from
More informationAcute and long-term treatment of PE. Cecilia Becattini University of Perugia
Acute and long-term treatment of PE Cecilia Becattini University of Perugia Acute and long-term treatment of VTE What is the optimal acute phase treatment for the patient? Intravenous thrombolysis One
More informationEdoxaban. Domenico Prisco Dipartimento di Medicina Sperimentale e Clinica Università di Firenze SOD Patologia Medica, AOU Careggi, Firenze
Edoxaban Domenico Prisco Dipartimento di Medicina Sperimentale e Clinica Università di Firenze SOD Patologia Medica, AOU Careggi, Firenze Bologna 8 novembre 2013 Disclosures: DP has received research support
More informationTechnician Objectives. Pharmacist Objectives. Replacing Warfarin. Gaps in Practice. Target-Specific Anticoagulants: Clinical Update and
Target-Specific Anticoagulants: Clinical Update and Considerations Erika Hellenbart, PharmD, BCPS September 13,2014 Target-Specific Anticoagulants: Clinical Update and Considerations Erika Hellenbart,
More informationDuration of Anticoagulation? Peter Verhamme MD, PhD Department of Cardiovascular Medicine University of Leuven Belgium
Duration of Anticoagulation? Peter Verhamme MD, PhD Department of Cardiovascular Medicine University of Leuven Belgium Disclosures Honoraria and research support: Daiichi-Sankyo, Boehringer Ingelheim,
More information